Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial
Circulation. 2022; online ahead of print DOI: 10.1161/CIRCULATIONAHA.122.062769
In the EMPA-HEART 2 CardioLink-7 trial, 169 individuals without diabetes but with risk factors for adverse cardiac remodelling were randomised to empagliflozin 10 mg/day or placebo for 6 months. The primary outcome, change in LVMi from baseline to 6 months, was not significantly different with empagliflozin and placebo, and there were no clinically meaningful between-group differences in LV volumes (diastolic and systolic indexed to baseline BSA) or ejection fraction.